World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
About Valneva SEValneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
140 articles about Valneva SE
Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and R&D expense guidance.
The French vaccine maker on Monday said it sold a priority review voucher, which was awarded by the FDA in November 2023 alongside an approval for its chikungunya vaccine, to an undisclosed buyer.
Valneva SE announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
Valneva SE, a specialty vaccine company, announced that the Company is modifying its financial guidance for 2023.
Saint-Herblain, December 20, 2023 – Valneva SE, a specialty vaccine company, announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting held on December 20, 2023.
Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®
Albumedix Ltd announces that Recombumin® is critical to the manufacture of the first FDA- licensed chikungunya vaccine.
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
Valneva SE announced the availability of documentation for its Extraordinary General Meeting which will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France.
Following a more than two-month delay to its PDUFA action date, Valneva’s chikungunya vaccine Ixchiq has won the regulatory race beating biotech Bavarian Nordic.
Valneva SE, a specialty vaccine company, reported consolidated financial results for the first nine months of the year, ended September 30, 2023.
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
Valneva SE announces the submission of a marketing application with the European Medicines Agency for approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553.
Valneva SE, a specialty vaccine company, announces it will present on the mosquito-borne chikungunya disease at several leading scientific conferences during the fourth quarter of 2023.
Valneva SE, a specialty vaccine company, reported its consolidated financial results for the first half of the year, ended June 30, 2023.
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. announced positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, when given as a booster.
Valneva SE announced that Health Canada has completed screening validation of the Company’s regulatory application for marketing approval of its single-shot chikungunya vaccine candidate VLA1553 in persons aged 18 years and above, and has determined that the New Drug Submission application is sufficiently complete to permit a substantive review.
Valneva SE, a specialty vaccine company, announced an agreement to increase the principal amount of its existing $100 million senior secured debt financing agreement with funds managed by leading U.S. healthcare investment firms Deerfield Management Company and OrbiMed.
Valneva’s chikungunya vaccine candidate will have to wait three more months for a decision from the regulator, potentially giving rival Bavarian Nordic additional time to catch up.
The Danish company’s vaccine candidate met all co-primary endpoints in a late-stage study in adults and adolescents just months after publishing trial data for elderly patients, as it seeks to challenge Valneva.
Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors
ValnevaSE, a specialty vaccine company, announced that its Supervisory Board has recommended a change of governance model.
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
ValnevaSE announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held in Lyon, France.
Valneva’s chikungunya vaccine candidate VLA1553 showed that the shot safely and rapidly induced high rates of seroprotection. Merck earlier in 2023 discontinued its chikungunya program.